Among these, SNORA15/CCT6A, which we found genetically altered in a high percentage of HNSC, KIRC, SKCM and UCEC patients, but overexpressed in around 5% of SKCM, BRCA, and LUSC patients (with an amplification/overexpression correspondence only for melanomas, where CCT6A overexpression has previously been linked to drug resistance [76], but the contribution of SNORA15 remains unexplored). Here, CCT6A is linked to melanoma.